

Edgar Filing: GENOMED INC - Form 8-K

GENOMED INC
Form 8-K
May 18, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

MAY 16, 2005

Date of Report (Date of earliest event reported)

GENOMED, INC.

(Exact name of registrant as specified in its charter)

Florida	000-49720	43-1916702
----- (State or other jurisdiction of incorporation)	----- (Commission File Number)	----- (IRS Employer Identification No.)

9666 OLIVE BOULEVARD, SUITE 300, ST. LOUIS, MISSOURI 63131

(Address of principal executive offices) (Zip Code)

(314) 983-9933

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: GENOMED INC - Form 8-K

ITEM 8.01 OTHER EVENTS.

On May 16, 2005, we filed a Form 12b-25 reporting that our quarterly report on Form 10-Q for the quarter ended March 31, 2005 would not be filed by the subject report's due date. We also reported that because we have not completed our quarterly financial statements and have recently engaged a new accounting firm to serve as our auditor, we would be unable to file the subject report by the fifth calendar day following the prescribed due date. We intend to file the subject report as soon as possible thereafter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOMED, INC.

Date: May 18, 2005

By: /s/ David Moskowitz

Dr. David Moskowitz
Chief Executive Officer